Skip to main content

Table 3 Incidence of adverse reactions to cluster immunotherapy during the build-up phase and first year of the maintenance phase

From: Observational study on the tolerability of cluster subcutaneous immunotherapy in patients with rhinoconjunctivitis with or without asthma sensitized to pollen: the SIMO study

Reference Adverse reactions by number of patients at risk (adverse reactions/number of patients) % Adverse reactions by number of AIT injections (adverse reactions/number of injections*) %
Local reactions Systemic reactions Local reactions Systemic reactions
Solá, 2018 (60/110) 54.5 (95% CI 44.8–64) (9/110) 8.2 (95% CI 3.8–15) (60/110*(6 + 12)) 3.03 (95% CI 2.3–3.9) (9/110*(6 + 12)) 0.46 (95% CI 0.2–0.9)
Walker, 2001 [7] (0/22) 0 (4/22) 18.2 (0/22*(11 + 11)) 0 (4/22*(11 + 11)) 0.8
Crimi, 2004 [9] (3/15) 20 (0/15) 0 (3/15*(12 + 10)) 0.9 (0/15*(12 + 10)) 0
Nanda, 2004 [10] (0/20) 0 (1/20) 5 (0/20*(9 + 11)) 0 (1/20*(9 + 11)) 0.3
Tabar, 2005 [11] (7/120) 5.8 (4/120) 3.3 (7/120*(16 + 11)) 0.2 (4/120*(16 + 11)) 0.1
Colás, 2006 [13] (16/41) 39 (16/41) 39 (16/41*(7 + 12)) 2.1 (16/41*(7 + 12)) 2.1
Subiza, 2008 [14] (7/22) 31.8 (0/22) 0 (7/22*(5 + 12)) 1.9 (0/22*(5 + 12)) 0
Zhang, 2009 [16] (18/45) 40 (5/45) 11.1 (18/45*(14 + 11)) 1.6 (5/45*(14 + 11)) 0.4
Lou, 2012 [17]
Klimek, 2014 [18] (7/61) 11.5 (5/61) 8.2 (7/61*(5 + 11)) 0.7 (5/61*(5 + 11)) 0.5
González-Gutiérrez, 2012 [6] (32/127) 25.2 (14/127) 11 (32/127*(7 + 11)) 1.4 (14/127*(7 + 11)) 0.6
(26/177) 14.7 (20/177) 11.3 (26/177*(5 + 11)) 0.9 (20/177*(5 + 11)) 0.7
  1. *Number of AIT injections calculated as number of patients multiplied by number of injections in the build-up phase plus number of injections in the first year of the maintenance phase